A Prospective Trial Evaluating the Efficacy and Tumor Immune Microenvironment Remodeling Induced by SFI Plus PD-1 Inhibitors and PBC in Resectable NSCLC
A Prospective Trial Evaluating the Efficacy and Tumor Immune Microenvironment Remodeling Induced by SFI Plus PD-1 Inhibitors and PBC in Resectable NSCLC
Not yet recruiting · NCT07843251 · Registry updated 2026-09-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Prospective Trial Evaluating the Efficacy and Tumor Immune Microenvironment Remodeling Induced by SFI Plus PD-1 Inhibitors and PBC in Resectable NSCLC | Resectable Locally Advanced Non-Squamous NSCLC; Tear Disorder | Not yet recruiting | Phase 4 | 2026-09-28 | NCT07843251 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Anhui Provincial Cancer Hospital | 32 |
| Livzon Pharmaceutical Group Inc. | 3 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||